| Year |
Citation |
Score |
| 2023 |
Gulen AE, Rudraboina R, Tarique M, Ulker V, Shirwan H, Yolcu ES. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer. Cancer Immunology, Immunotherapy : Cii. 72: 3567-3579. PMID 37605009 DOI: 10.1007/s00262-023-03507-2 |
0.346 |
|
| 2023 |
Coronel MM, Linderman SW, Martin KE, Hunckler MD, Medina JD, Barber G, Riley K, Yolcu ES, Shirwan H, García AJ. Delayed graft rejection in autoimmune islet transplantation via biomaterial immunotherapy. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 37543091 DOI: 10.1016/j.ajt.2023.07.023 |
0.309 |
|
| 2023 |
Shrestha P, Turan A, Batra L, Gulen AE, Sun Z, Tan H, Askenasy N, Shirwan H, Yolcu ES. Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease. Blood Advances. PMID 36780582 DOI: 10.1182/bloodadvances.2022008495 |
0.369 |
|
| 2022 |
Medina JD, Barber GF, Coronel MM, Hunckler MD, Linderman SW, Quizon MJ, Ulker V, Yolcu ES, Shirwan H, García AJ. A hydrogel platform for co-delivery of immunomodulatory proteins for pancreatic islet allografts. Journal of Biomedical Materials Research. Part A. PMID 35841329 DOI: 10.1002/jbm.a.37429 |
0.351 |
|
| 2020 |
Coronel MM, Martin KE, Hunckler MD, Barber G, O'Neill EB, Medina JD, Opri E, McClain CA, Batra L, Weaver JD, Lim HS, Qiu P, Botchwey EA, Yolcu ES, Shirwan H, et al. Immunotherapy via PD-L1-presenting biomaterials leads to long-term islet graft survival. Science Advances. 6: eaba5573. PMID 32923626 DOI: 10.1126/Sciadv.Aba5573 |
0.368 |
|
| 2020 |
Shrestha P, Batra L, Tariq Malik M, Tan M, Yolcu ES, Shirwan H. Immune checkpoint CD47 molecule engineered islets mitigate instant blood-mediated inflammatory reaction and show improved engraftment following intraportal transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 32342638 DOI: 10.1111/Ajt.15958 |
0.436 |
|
| 2020 |
Batra L, Shrestha P, Zhao H, Woodward KB, Togay A, Tan M, Grimany-Nuno O, Malik MT, Coronel MM, García AJ, Shirwan H, Yolcu ES. Localized Immunomodulation with PD-L1 Results in Sustained Survival and Function of Allogeneic Islets without Chronic Immunosuppression. Journal of Immunology (Baltimore, Md. : 1950). PMID 32253240 DOI: 10.4049/Jimmunol.2000055 |
0.437 |
|
| 2020 |
Shirwan H, Batra L, Malik MT, Shrestha P, Hawthorne JL, Yolcu ES. Abstract 4516: SA-4-1BBL as a novel agonist of CD137 has immunoprevention efficacy against various tumor types Immunology. 80: 4516-4516. DOI: 10.1158/1538-7445.Am2020-4516 |
0.447 |
|
| 2020 |
Batra L, Shrestha P, Zhao H, Woodward KB, Togay A, Tan M, Grimany-Nuno O, Malik MT, Coronel MM, García AJ, Shirwan H, Yolcu E. Immunomodulation With Sa-Pdl1 Protein On Pancreatic Islets Promotes Indefinite Graft Survival In Allogeneic Recipients Transplantation. 104. DOI: 10.1097/01.Tp.0000699084.35417.96 |
0.304 |
|
| 2020 |
Shrestha P, Batra L, Malik MT, Tan M, Yolcu E, Shirwan H. Islets Engineered With Cd47 Innate Immune Checkpoint Protein Show Enhanced Engraftment Following Intraportal Transplantation By Mitigating Instant Blood Mediated Inflammatory Reaction Transplantation. 104. DOI: 10.1097/01.Tp.0000698308.12179.64 |
0.397 |
|
| 2019 |
Woodward KB, Zhao H, Shrestha P, Batra L, Tan M, Grimany-Nuno O, Bandura-Morgan L, Askenasy N, Shirwan H, Yolcu ES. Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 31850658 DOI: 10.1111/Ajt.15747 |
0.435 |
|
| 2019 |
Yerneni SS, Lathwal S, Shrestha P, Shirwan H, Matyjaszewski K, Weiss L, Yolcu ES, Campbell PG, Das SR. Rapid On-Demand Extracellular Vesicle Augmentation with Versatile Oligonucleotide Tethers. Acs Nano. PMID 31436946 DOI: 10.1021/Acsnano.9B04651 |
0.363 |
|
| 2019 |
Bowen W, Batra L, Pulsifer AR, Yolcu ES, Lawrenz MB, Shirwan H. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Vaccine. PMID 31416643 DOI: 10.1016/J.Vaccine.2019.07.103 |
0.399 |
|
| 2019 |
Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES, Shirwan H. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4 T and Natural Killer Cells. Cancer Research. 79: 783-794. PMID 30770367 DOI: 10.1158/0008-5472.Can-18-2401 |
0.492 |
|
| 2019 |
Garza-Morales R, Perez-Trujillo JJ, Martinez-Jaramillo E, Saucedo-Cardenas O, Loera-Arias MJ, Garcia-Garcia A, Rodriguez-Rocha H, Yolcu E, Shirwan H, Gomez-Gutierrez JG, Montes-de-Oca-Luna R. A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model. Cancers. 11. PMID 30650588 DOI: 10.3390/Cancers11010096 |
0.421 |
|
| 2019 |
Shirwan H, Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES. Abstract 4145: A novel form of 4-1BB agonist shows robust immune protection against various tumor types through CD4+memory-like T and NK cell axis Cancer Research. 79: 4145-4145. DOI: 10.1158/1538-7445.Sabcs18-4145 |
0.496 |
|
| 2018 |
Skoumal M, Woodward KB, Zhao H, Wang F, Yolcu ES, Pearson RM, Hughes KR, García AJ, Shea LD, Shirwan H. Localized immune tolerance from FasL-functionalized PLG scaffolds. Biomaterials. 192: 271-281. PMID 30458362 DOI: 10.1016/J.Biomaterials.2018.11.015 |
0.353 |
|
| 2018 |
Weaver JD, Headen DM, Coronel MM, Hunckler MD, Shirwan H, García AJ. Synthetic poly(ethylene glycol)-based microfluidic islet encapsulation reduces graft volume for delivery to highly vascularized and retrievable transplant site. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 30378751 DOI: 10.1111/Ajt.15168 |
0.343 |
|
| 2018 |
Headen DM, Woodward KB, Coronel MM, Shrestha P, Weaver JD, Zhao H, Tan M, Hunckler MD, Bowen WS, Johnson CT, Shea L, Yolcu ES, García AJ, Shirwan H. Local immunomodulation with Fas ligand-engineered biomaterials achieves allogeneic islet graft acceptance. Nature Materials. PMID 29867165 DOI: 10.1038/S41563-018-0099-0 |
0.434 |
|
| 2018 |
Martinez-Jaramillo E, Garza-Morales R, Wechman SL, Montes de Oca-Luna R, Saucedo-Cardenas O, Shirwan H, Yolcu E, McMasters KM, Gomez-Gutierrez JG. Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis. Cancer Investigation. 1-9. PMID 29388837 DOI: 10.1080/07357907.2018.1430812 |
0.318 |
|
| 2018 |
Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Review of Vaccines. PMID 29372660 DOI: 10.1080/14760584.2018.1434000 |
0.441 |
|
| 2018 |
Shirwan H. Induction of tolerance to allogeneic islet grafts using an immunomodulatory biomaterial Journal of Cell Science & Therapy. 9. DOI: 10.4172/2157-7013-C1-040 |
0.325 |
|
| 2018 |
Shrestha P, Bowen WS, Batra L, Tan M, Yolcu ES, Shirwan H. CD47 Overcomes Early Loss of Pancreatic Islet Grafts Transplanted Intraportally Transplantation. 102: S47. DOI: 10.1097/01.Tp.0000542608.84915.B0 |
0.428 |
|
| 2017 |
Garza-Morales R, Yaddanapudi K, Perez-Hernandez R, Riedinger E, McMasters KM, Shirwan H, Yolcu E, Gomez-Gutierrez JG. Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis. Cancer Biology & Therapy. 0. PMID 29252087 DOI: 10.1080/15384047.2017.1416274 |
0.355 |
|
| 2017 |
Weaver JD, Headen DM, Aquart J, Johnson CT, Shea LD, Shirwan H, García AJ. Vasculogenic hydrogel enhances islet survival, engraftment, and function in leading extrahepatic sites. Science Advances. 3: e1700184. PMID 28630926 DOI: 10.1126/Sciadv.1700184 |
0.332 |
|
| 2017 |
Yolcu ES, Shirwan H, Askenasy N. Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes. Frontiers in Immunology. 8: 342. PMID 28396667 DOI: 10.3389/Fimmu.2017.00342 |
0.358 |
|
| 2017 |
Yolcu ES, Shirwan H, Askenasy N. Mechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective. Stem Cells Translational Medicine. PMID 28186688 DOI: 10.1002/Sctm.16-0358 |
0.394 |
|
| 2017 |
Shirwan H. Targeted deletion of pathogenic T effector cells as a robust means of allograft tolerance Journal of Cell Science and Therapy. 8. DOI: 10.4172/2157-7013.C1.037 |
0.371 |
|
| 2016 |
Barsoumian HB, Yolcu ES, Shirwan H. 4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression. Plos One. 11: e0153088. PMID 27049955 DOI: 10.1371/Journal.Pone.0153088 |
0.412 |
|
| 2016 |
Srivastava AK, Yolcu ES, Dinc G, Sharma RK, Shirwan H. SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer. Oncoimmunology. 5: e1064580. PMID 26942082 DOI: 10.1080/2162402X.2015.1064580 |
0.389 |
|
| 2015 |
Woodward KB, Wang F, Zhao H, Yolcu ES, Shirwan H. Novel technologies to engineer graft for tolerance induction. Current Opinion in Organ Transplantation. PMID 26626421 DOI: 10.1097/Mot.0000000000000270 |
0.316 |
|
| 2014 |
Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Research. 74: 6441-51. PMID 25252915 DOI: 10.1158/0008-5472.Can-14-1768-A |
0.519 |
|
| 2014 |
Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant. Vaccine. 32: 5035-40. PMID 25045812 DOI: 10.1016/J.Vaccine.2014.07.015 |
0.419 |
|
| 2014 |
Shirwan H, Yolcu ES, Sharma RK, Zaho H, Grimany-Nuno O. The direct display of costimulatory proteins on tumor cells as a means of vaccination for cancer immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 1139: 269-85. PMID 24619687 DOI: 10.1007/978-1-4939-0345-0_23 |
0.462 |
|
| 2014 |
Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Review of Vaccines. 13: 387-98. PMID 24521311 DOI: 10.1586/14760584.2014.880340 |
0.509 |
|
| 2014 |
Zhao H, Yolcu E, Woodward K, Ahmad N, Bandura-Morgan L, Askenasy N, Shirwan H. Rat Islets Engineered to Display On Their Surface an Apoptotic Form of FasL Protein Induces Robust Localized Tolerance Through CD4+CD25+Foxp3+ Treg Cells in Mice. Transplantation. 98: 29. DOI: 10.1097/00007890-201407151-00092 |
0.401 |
|
| 2013 |
Sharma RK, Yolcu ES, Srivastava AK, Shirwan H. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. Plos One. 8: e73145. PMID 24066030 DOI: 10.1371/Journal.Pone.0073145 |
0.506 |
|
| 2013 |
Yolcu ES, Kaminitz A, Mizrahi K, Ash S, Yaniv I, Stein J, Shirwan H, Askenasy N. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease. Experimental Hematology. 41: 903-11. PMID 23743300 DOI: 10.1016/J.Exphem.2013.04.016 |
0.456 |
|
| 2013 |
Shirwan H, Sharma RK, Srivastava AK, Yolcu ES. Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines. Oncoimmunology. 2: e23440. PMID 23734306 DOI: 10.4161/Onci.23440 |
0.421 |
|
| 2013 |
Kaminitz A, Yolcu ES, Mizrahi K, Shirwan H, Askenasy N. Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice through local and systemic immunomodulation. International Immunology. 25: 485-94. PMID 23657001 DOI: 10.1093/Intimm/Dxt016 |
0.445 |
|
| 2012 |
Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. Plos One. 7: e48463. PMID 23144888 DOI: 10.1371/Journal.Pone.0048463 |
0.475 |
|
| 2012 |
Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. Plos One. 7: e42459. PMID 22870329 DOI: 10.1371/Journal.Pone.0042459 |
0.475 |
|
| 2012 |
Sun Z, Shirwan H, Singh NP, Askenasy N, Yolcu ES. T Cells Engineered to Display on their Surface a Novel Form of Fasl Fail to Induce GVHD Following Transplantation Into Irradiated Allogeneic Hosts Transplantation Journal. 94: 558. DOI: 10.1097/00007890-201211271-01077 |
0.371 |
|
| 2012 |
Yolcu ES, Zhao H, Woodward KB, Shirwan H. Pancreatic Islets Engineered with SA-Fasl Protein Induces Localized Tolerance that Is Effective in Preventing the Rejection of a Second Set Unmanipulated Islet Grafts Transplanted Under the Contralateral Kidney Capsule During the Induction, but not Maintenance Phase Transplantation Journal. 94: 484. DOI: 10.1097/00007890-201211271-00925 |
0.326 |
|
| 2012 |
Zhao H, Yolcu E, Woodward K, Shirwan H. Allogeneic Pancreatic Islets Engineered to Display on their Surface a Novel Form of FasL Protein Induces both Allo and Autotolerance in Spontaneously Diabetic NOD Mouse Model Transplantation Journal. 94: 349. DOI: 10.1097/00007890-201211271-00648 |
0.304 |
|
| 2011 |
Yolcu ES, Zhao H, Bandura-Morgan L, Lacelle C, Woodward KB, Askenasy N, Shirwan H. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. Journal of Immunology (Baltimore, Md. : 1950). 187: 5901-9. PMID 22068235 DOI: 10.4049/Jimmunol.1003266 |
0.455 |
|
| 2011 |
Kaminitz A, Yolcu ES, Askenasy EM, Stein J, Yaniv I, Shirwan H, Askenasy N. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. Plos One. 6: e21630. PMID 21738739 DOI: 10.1371/Journal.Pone.0021630 |
0.389 |
|
| 2011 |
Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. Journal of Autoimmunity. 37: 39-47. PMID 21497486 DOI: 10.1016/J.Jaut.2011.03.003 |
0.464 |
|
| 2011 |
Srivastava A, Sharma R, Zhao H, Yolcu E, Shirwan H. Abstract 765: Costimulatory SA-4-1BBL and monophosphoryl lipid A as novel adjuvant system for the development of cancer vaccines with robust therapeutic efficacy Cancer Research. 71: 765-765. DOI: 10.1158/1538-7445.Am2011-765 |
0.486 |
|
| 2010 |
Gu X, Yang J, Zhao H, Yolcu ES, Shirwan H. [Allograft tolerance induced by FasL chimeric protein decorated donor splenocytes]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]. 48: 702-5. PMID 20646556 DOI: 10.3760/Cma.J.Issn.0529-5815.2010.09.015 |
0.347 |
|
| 2010 |
Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S, Shirwan H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine. 28: 5794-802. PMID 20603135 DOI: 10.1016/J.Vaccine.2010.06.073 |
0.454 |
|
| 2010 |
Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Therapy. 17: 730-41. PMID 20559332 DOI: 10.1038/Cgt.2010.29 |
0.73 |
|
| 2010 |
Pearl-Yafe M, Mizrahi K, Stein J, Yolcu ES, Kaplan O, Shirwan H, Yaniv I, Askenasy N. Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells (Dayton, Ohio). 28: 1270-80. PMID 20506490 DOI: 10.1002/Stem.448 |
0.334 |
|
| 2010 |
Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Research. 70: 3945-54. PMID 20406989 DOI: 10.1158/0008-5472.Can-09-4480 |
0.764 |
|
| 2010 |
Sharma RK, Schabowsky R, Srivastava AK, Yolcu ES, Elpek KG, Zhao H, Madireddi S, Shirwan H. Abstract 2416: SA-4-1BBL costimulatory ligand as an immune modulator and effective vehicle to deliver antigens into dendritic cells for the generation of robust therapeutic antitumor immune responses Cancer Research. 70: 2416-2416. DOI: 10.1158/1538-7445.Am10-2416 |
0.759 |
|
| 2010 |
Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Abstract 1501: Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy Cancer Research. 70: 1501-1501. DOI: 10.1158/1538-7445.Am10-1501 |
0.709 |
|
| 2010 |
Sharma R, Schabowsky R, Srivastava A, Yolcu E, Elpek K, Zhao H, Madireddi S, Shirwan H. SA-4-1BBL Serves as an Immune Modulator as well as Vehicle to Deliver Antigens into Dendritic Cells in vivo for Generation of Robust Immunity for Eradication of Tumors Clinical Immunology. 135: S86. DOI: 10.1016/J.Clim.2010.03.258 |
0.71 |
|
| 2009 |
Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28: 512-22. PMID 19836479 DOI: 10.1016/J.Vaccine.2009.09.127 |
0.727 |
|
| 2009 |
Schabowsky RH, Sharma RK, Madireddi S, Srivastava A, Yolcu ES, Shirwan H. ProtEx technology for the generation of novel therapeutic cancer vaccines. Experimental and Molecular Pathology. 86: 198-207. PMID 19454266 DOI: 10.1016/J.Yexmp.2009.01.010 |
0.469 |
|
| 2009 |
Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Research. 69: 4319-26. PMID 19435920 DOI: 10.1158/0008-5472.Can-08-3141 |
0.758 |
|
| 2008 |
Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. Journal of Immunology (Baltimore, Md. : 1950). 181: 931-9. PMID 18606644 DOI: 10.4049/Jimmunol.181.2.931 |
0.466 |
|
| 2008 |
Sun Z, Shirwan H, Singh N, Askenasy N, Yolcu ES. A Novel Approach to Prevent GvHD: Donor Cells Engineered to Display on Their Surface a Recombinant Form of FasL Protein Effectively Prevent Lethal GvHD in a Mouse Model Blood. 112: 3519-3519. DOI: 10.1182/Blood.V112.11.3519.3519 |
0.451 |
|
| 2008 |
Sharma R, Elpek K, Yolcu E, Schabowsky R, Zhao H, Bandura-Morgon L, Shirwan H. Su.60. A Novel Vaccine Concept for Treatment of Cervical Cancer Clinical Immunology. 127: S143-S144. DOI: 10.1016/J.Clim.2008.03.411 |
0.683 |
|
| 2007 |
Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Current Opinion in Investigational Drugs (London, England : 2000). 8: 1002-8. PMID 18058571 |
0.419 |
|
| 2007 |
Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Journal of Immunology (Baltimore, Md. : 1950). 179: 7295-304. PMID 18025172 DOI: 10.4049/Jimmunol.179.11.7295 |
0.763 |
|
| 2007 |
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Experimental Hematology. 35: 1601-12. PMID 17889725 DOI: 10.1016/J.Exphem.2007.07.010 |
0.337 |
|
| 2007 |
Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I, Askenasy N. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells (Dayton, Ohio). 25: 3194-203. PMID 17872500 DOI: 10.1634/Stemcells.2007-0402 |
0.341 |
|
| 2007 |
Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of Immunology (Baltimore, Md. : 1950). 178: 6840-8. PMID 17513732 DOI: 10.4049/Jimmunol.178.11.6840 |
0.741 |
|
| 2007 |
Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells (Dayton, Ohio). 25: 1448-55. PMID 17363551 DOI: 10.1634/Stemcells.2007-0013 |
0.377 |
|
| 2007 |
Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Molecular Immunology. 44: 2884-92. PMID 17324464 DOI: 10.1016/J.Molimm.2007.01.014 |
0.763 |
|
| 2007 |
Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunology, Immunotherapy : Cii. 56: 997-1007. PMID 17146630 DOI: 10.1007/S00262-006-0247-2 |
0.689 |
|
| 2006 |
Singh NP, Miller RW, Yolcu ES, Kilinc MO, Oechsli M, Huseby R, Taylor DD, Perry MT, Larocca RV, Shirwan H. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Human Gene Therapy. 17: 334-46. PMID 16544982 DOI: 10.1089/Hum.2006.17.334 |
0.496 |
|
| 2006 |
Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Experimental and Molecular Pathology. 80: 252-61. PMID 16487512 DOI: 10.1016/J.Yexmp.2005.12.004 |
0.38 |
|
| 2006 |
Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 28: 211-22. PMID 16435302 DOI: 10.1002/Bies.20356 |
0.405 |
|
| 2006 |
Franke DD, Shirwan H. Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in non-obese diabetic mice. International Immunology. 18: 453-8. PMID 16415097 DOI: 10.1093/Intimm/Dxh385 |
0.724 |
|
| 2006 |
Shirwan H. Allograft tolerance: is it a journey towards achieving the impossible? Current Opinion in Organ Transplantation. 11: 351-352. DOI: 10.1097/01.Mot.0000236695.22340.24 |
0.307 |
|
| 2005 |
Singh NP, Yolcu ES, Askenasy N, Shirwan H. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation. Annals of the New York Academy of Sciences. 1056: 344-58. PMID 16387700 DOI: 10.1196/Annals.1352.036 |
0.407 |
|
| 2005 |
Köksoy S, Elpek KG, Yolcu ES, Shirwan H. Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells. Transplantation. 79: 1492-7. PMID 15940037 DOI: 10.1097/01.Tp.0000159870.01567.02 |
0.731 |
|
| 2005 |
Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood. 105: 1396-404. PMID 15486063 DOI: 10.1182/Blood-2004-06-2364 |
0.373 |
|
| 2004 |
Singh N, Yolcu ES, Miller RW, Shirwan H, Huseby RM, Kilinc O, Taylor D, Oechsli M, Larocca R. Primary tumor cells from cancer patients "decorated" with a novel form of CD80 protein effectively induce autologous T-cell responses ex-vivo. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2580. PMID 28015279 DOI: 10.1200/jco.2004.22.14_suppl.2580 |
0.381 |
|
| 2004 |
Köksoy S, Kakoulidis TP, Shirwan H. Chronic heart allograft rejection in rats demonstrates a dynamic interplay between IFN-gamma and IL-10 producing T cells. Transplant Immunology. 13: 201-9. PMID 15381203 DOI: 10.1016/J.Trim.2004.03.001 |
0.449 |
|
| 2004 |
Singh NP, Guo L, Que X, Shirwan H. Blockade of indirect recognition mediated by CD4+ T cells leads to prolonged cardiac xenograft survival. Xenotransplantation. 11: 33-42. PMID 14962291 DOI: 10.1111/J.1399-3089.2004.00079.X |
0.437 |
|
| 2003 |
Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Research. 63: 4067-73. PMID 12874008 |
0.387 |
|
| 2003 |
Shirwan H, Mhoyan A, Yolcu ES, Que X, Ibrahim S. Chronic cardiac allograft rejection in a rat model disparate for one single class I MHC molecule is associated with indirect recognition by CD4(+) T cells. Transplant Immunology. 11: 179-85. PMID 12799202 DOI: 10.1016/S0966-3274(03)00004-2 |
0.449 |
|
| 2003 |
Shirwan H, Mhoyan A, Kakoulidis TP, Yolcu ES, Ibrahim S. Prevention of chronic rejection with immunoregulatory cells induced by intrathymic immune modulation with class I allopeptides. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 3: 581-9. PMID 12752314 DOI: 10.1034/J.1600-6143.2003.00052.X |
0.405 |
|
| 2003 |
Mhoyan A, Wu GD, Kakoulidis TP, Que X, Yolcu ES, Cramer DV, Shirwan H. Predominant expression of the Th2 response in chronic cardiac allograft rejection. Transplant International : Official Journal of the European Society For Organ Transplantation. 16: 464-73. PMID 12712237 DOI: 10.1007/S00147-003-0590-6 |
0.378 |
|
| 2003 |
Askenasy N, Yolcu ES, Wang Z, Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation. 107: 1525-31. PMID 12654611 DOI: 10.1161/01.Cir.0000064893.96179.7E |
0.402 |
|
| 2003 |
Singh NP, Guo L, Mhoyan A, Shirwan H. Predominant expression of Th2 cytokines and interferon-gamma in xenogeneic cardiac grafts undergoing acute vascular rejection. Transplantation. 75: 586-90. PMID 12640294 DOI: 10.1097/01.Tp.0000052594.83318.68 |
0.332 |
|
| 2003 |
Askenasy N, Yolcu ES, Shirwan H, Wang Z, Farkas DL, Yoleuk ES. Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients. Stem Cells (Dayton, Ohio). 21: 200-7. PMID 12634416 DOI: 10.1634/Stemcells.21-2-200 |
0.32 |
|
| 2002 |
Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity. 17: 795-808. PMID 12479825 DOI: 10.1016/S1074-7613(02)00482-X |
0.375 |
|
| 2001 |
Shirwan H, Mhoyan A, Yolcu E, Ibrahim S. Intrathymic immune regulation with donor class I allopeptides leads to the development of immunoregulatory cells that maintain tolerance to cardiac allografts. Transplantation Proceedings. 33: 80. PMID 11266712 DOI: 10.1016/S0041-1345(00)01912-6 |
0.399 |
|
| 2000 |
Huang Y, Ildstad ST, Neipp M, Shirwan H. Mouse xenoantigens contribute to rat T-cell Vbeta repertoire generation in mixed xenogeneic bone marrow chimeras. Immunology. 100: 317-25. PMID 10929053 DOI: 10.1046/J.1365-2567.2000.00049.X |
0.303 |
|
| 2000 |
Shirwan H, Mhoyan A, Sherif I. PREVENTION OF CHRONIC REJECTION WITH IMMUNOREGULATORY CELLS INDUCED BY INTRATHYMIC IMMUNE MODULATION WITH CLASS I MHC ALLOPEPTIDES.: Abstract# 129 Transplantation. 69. DOI: 10.1097/00007890-200004271-00129 |
0.386 |
|
| 1999 |
Shirwan H. Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role? Transplantation. 68: 715-26. PMID 10515369 DOI: 10.1097/00007890-199909270-00001 |
0.456 |
|
| 1999 |
Shirwan H, Barwari L, Khan NS. Immune nonresponsiveness to cardiac allografts by intrathymic inoculation of donor class I allopeptides is associated with high levels of transcripts for Th2 cytokines in the graft. Transplantation Proceedings. 31: 123-4. PMID 10083039 DOI: 10.1016/S0041-1345(98)01469-9 |
0.349 |
|
| 1999 |
Mhoyan A, Que X, Shirwan H. INTRATHYMIC IMMUNE NONRESPONSIVENESS WITH CLASS I MHC ALLOPEPTIDES IS ASSOCIATED WITH SUPPRESSIVE IMMUNE MECHANISMS Transplantation. 67: S66. DOI: 10.1097/00007890-199904150-00267 |
0.333 |
|
| 1998 |
Cramer DV, Wu G, Kearns-Jonker M, Gochi E, Wakiyama S, Shirwan H, Borie D. The humoral response to xenografts is controlled by a restricted repertoire of immunoglobulin VH genes. Transplantation. 66: 1375-1383. PMID 9846525 DOI: 10.1097/00007890-199811270-00019 |
0.307 |
|
| 1998 |
Shirwan H, Barwari L, Khan N. IMMUNE NONRESPONSIVENESS TO CARDIAC ALLOGRAFTS BY INTRATHYMIC INOCULATION OF DONOR CLASS I ALLOPEPTIDES IS ASSOCIATED WITH HIGH LEVELS OF TRANSCRIPTS FOR TH2 CYTOKINES IN THE GRAFT Transplantation. 65: 177. DOI: 10.1097/00007890-199805131-00391 |
0.349 |
|
| 1997 |
Mhoyan A, Cramer DV, Baquerizo A, Shirwan H. Induction of allograft nonresponsiveness after intrathymic inoculation with donor class I allopeptides. I. Correlation of graft survival with antidonor IgG antibody subclasses. Transplantation. 64: 1665-1670. PMID 9422399 DOI: 10.1097/00007890-199712270-00006 |
0.359 |
|
| 1997 |
Shirwan H, Barwari L, Cramer DV. Rejection Of Cardiac Allografts By T Cells Expressing A Restricted Repertoire Of T-Cell Receptor Vbeta Genes Immunology. 90: 572-578. PMID 9176111 DOI: 10.1046/J.1365-2567.1997.00187.X |
0.376 |
|
| 1996 |
Shirwan H, Wang HK, Barwari L, Makowka L, Cramer DV. Pretransplant injection of allograft recipients with donor blood or lymphocytes permits allograft tolerance without the presence of persistent donor microchimerism. Transplantation. 61: 1382-6. PMID 8629301 DOI: 10.1097/00007890-199605150-00017 |
0.359 |
|
| 1995 |
Shirwan H, Cajulis E, Makowka L, Cramer DV. Differential usage of the T cell receptor repertoire for allorecognition of heart, liver, and kidney grafts. Transplantation. 59: 1709-1714. PMID 7604442 DOI: 10.1097/00007890-199506270-00012 |
0.37 |
|
| 1995 |
Shirwan H, Leamer M, Wang HK, Makowka L, Cramer DV. Peptides derived from α-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection Transplantation. 59: 401-409. DOI: 10.1097/00007890-199502000-00016 |
0.374 |
|
| Show low-probability matches. |